MARKET

ADXS

ADXS

Advaxis Inc
OTCQX

Real-time Quotes | Nasdaq Last Sale

0.068
+0.003
+4.78%
Closed 15:54 05/20 EDT
OPEN
0.065
PREV CLOSE
0.065
HIGH
0.068
LOW
0.065
VOLUME
536.62K
TURNOVER
37.16K
52 WEEK HIGH
0.760
52 WEEK LOW
0.055
MARKET CAP
9.90M
P/E (TTM)
-0.4561
1D
5D
1M
3M
1Y
5Y
BRIEF-Advaxis Applies To List Common Stock On Nasdaq Under Symbol "ADXS" - SEC Filing
reuters.com · 05/12 21:37
Advaxis to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
MONMOUTH JUNCTION, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that it will present data from the P...
GlobeNewswire · 04/27 14:00
Advaxis Announces Publication of ADXS-PSA Data in The Oncologist
ADXS-PSA in combination with KEYTRUDA® in metastatic castration-resistant prostate cancer (mCRPC) is associated with prolonged overall survival in this population, particularly in patients with visceral metastasis Median overall survival of 16.4 months for...
GlobeNewswire · 04/08 12:00
ADXS Investor Alert – Monteverde & Associates PC and Kahn Swick & Foti, LLC Obtain Material Disclosures Regarding the Upcoming Shareholder Vote for Advaxis, Inc. - ADXS
NEW YORK, March 28, 2022--Kahn Swick & Foti, LLC and Monteverde & Associates PC announce that, on March 28, 2022, Advaxis, Inc. issued a Supplemental Proxy Statement that includes additional clarifying information about how to vote regarding Proposal No. 1...
Business Wire · 03/28 16:59
Advaxis GAAP EPS of $0.00
Advaxis press release (OTC:ADXS): Q1 GAAP EPS of $0.00. As of January 31, 2022, the Company had approximately $36.5 million in cash and cash equivalents
Seekingalpha · 03/17 13:34
Advaxis  GAAP EPS of -$0.14 beats by $0.03, revenue of $3.24M beats by $0.25M
Advaxis  press release (OTC:ADXS): FY GAAP EPS of -$0.14 beats by $0.03. Revenue of $3.24M (+1196.0% Y/Y) beats by $0.25M. As of October 31, 2021, Advaxis had cash and cash equivalents of $41.6 million.
Seekingalpha · 02/14 21:44
Advaxis prices $5M in convertible redeemable preferred stock offering
Advaxis (OTC:ADXS) entered into an agreement with certain institutional investors for the private placement of 1M shares of Series D convertible redeemable preferred stock. The shares to be sold will have
Seekingalpha · 01/28 13:30
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement
MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company entered into an agre...
GlobeNewswire · 01/28 13:00
More
No Data
Learn about the latest financial forecast of ADXS. Analyze the recent business situations of Advaxis Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADXS stock price target is 2.250 with a high estimate of 2.250 and a low estimate of 2.250.
High2.250
Average2.250
Low2.250
Current 0.0680
EPS
Actual
Estimate
-0.04-0.03-0.02-0.01
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 59
Institutional Holdings: 10.89M
% Owned: 7.48%
Shares Outstanding: 145.64M
TypeInstitutionsShares
Increased
11
470.26K
New
5
500.02K
Decreased
6
347.46K
Sold Out
9
412.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.64%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Non-Executive Chairman/Independent Director
David Sidransky
President/Chief Executive Officer/Director
Kenneth Berlin
Non-Executive Vice Chairman/Independent Director
James Patton
Chief Financial Officer
Igor Gitelman
Executive Vice President
Andres Gutierrez
Independent Director
Roni Appel
Independent Director
Richard Berman
Independent Director
Samir Khleif
No Data
No Data
About ADXS
Advaxis, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of Listeria monocytogenes (Lm)-based antigen delivery products. The Company is using its Lm platform directed against tumor-specific targets to engage the patient's immune system to destroy tumor cells. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Its Lm platform technology has clinical activity in several programs. These Lm strains integrate multiple functions into a single immunotherapy as they access and direct antigen presenting cells to stimulate anti-tumor T-cell immunity, stimulate and activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment (TME) to enable the T-cells to eliminate tumors.

Webull offers kinds of Advaxis, Inc. stock information, including OTCQX:ADXS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADXS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADXS stock methods without spending real money on the virtual paper trading platform.